Skip to main content
SpringerLink
Log in

Clinical Pharmacology of Valpromide

  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Valpromide has been used as an antiepileptic and antipsychotic drug for the past 25 years in several European countries. Unlike its corresponding acid, valproic acid, whose pharmacokinetics have been quite extensively reviewed, and despite years of clinical use, it appears that no reviews have been written on the pharmacokinetics of valpromide. This article summarises and analyses its pharmacokinetics from various aspects, with a special emphasis on the differences between valpromide and valproic acid.

In humans, valpromide is a prodrug of valproic acid. Despite their chemical similarity, the pharmacokinetics of the 2 drugs in humans are quite distinct. Compared with valproic acid, valpromide has a very short half-life (mean ± SD: 0.84 ± 0.33h; n = 6), a high clearance value (70 ± 31 L/h) and a large volume of distribution (75 ± 13L). Despite its rapid biotransformation to valproic acid, valpromide has some special characteristics, such as its inhibition of the enzyme epoxide hydrolase which is responsible for the metabolism of carbamazepine-10,11-epoxide. This review discusses the pharmacokinetics of valpromide, the interactions between it and other drugs such as carbamazepine and amitriptyline, and its antiepileptic and antipsychotic activities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bialer M, Friedman M, Dubrovsky J, Raz I, Abramsky O. Pharmacokinetic evaluation of novel sustained release dosage forms of valproic acid. Biopharmaceutics and Drug Disposition 6: 401–411, 1985b

    Article  CAS  Google Scholar 

  • Bialer M, Friedman M, Rubinstein A. A rapid GLC assay for monitoring valproic acid and valpromide in plasma. Journal of Pharmaceutical Sciences 73: 991–993, 1984a

    Article  PubMed  CAS  Google Scholar 

  • Bialer M, Haj-Yehia A, Barzaghi N, Pisani F, Perucca E. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. European Journal of Clinical Pharmacology 38: 289–291, 1990

    Article  PubMed  CAS  Google Scholar 

  • Bialer M, Rubinstein A. A comparative study on the pharmacokinetics of valpromide after intravenous administration in dogs. Journal of Pharmacy and Pharmacology 35: 607–609, 1983

    Article  PubMed  CAS  Google Scholar 

  • Bialer M, Rubinstein A. Pharmacokinetics of valpromide in dogs after various modes of administration. Biopharmaceutics and Drug Disposition 5: 177–183, 1984

    Article  CAS  Google Scholar 

  • Bialer M, Rubinstein A, Dubrovsky J, Raz I, Abramsky O. A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans. International Journal of Pharmaceutics 23: 25–33, 1985a

    Article  CAS  Google Scholar 

  • Bialer M, Rubinstein A, Raz I, Abramsky O. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy subjects. European Journal of Clinical Pharmacology 27: 501–503, 1984b

    Article  PubMed  CAS  Google Scholar 

  • Billig H, Ziv E, Bar-On H, Bialer M. The disposition of valpromide in rats and in the isolated perfused rat liver. Drug Metabolism and Disposition 18: 238–244, 1990

    PubMed  CAS  Google Scholar 

  • Bouchard JM, Pujol M. Thérapeutique méconnue ou 4 grandes indications du Dépamide. Information Psvchiatry 51: 341–346, 1975

    Google Scholar 

  • Carraz G, Darbon M, Lebreton S, Beriel H. Propriétés pharma-codynamiques de l’acide n-dipropylacétique et de ses dérives. Quatrième mémoire: le n-dipropyl acétamide. Therapy 19: 469–475, 1964

    Google Scholar 

  • Emrich HM. Anti-epileptic agents: II. Diphenylhydantoin, dipro-pylacetamide, valproate and progabide. In Johnson (Ed.) Lithium combination treatment, pp. 156–163, Krager, Basel, 1987

    Google Scholar 

  • Favel P, Cartier J, Gratadou JP, Gratadou G. Depamide® in the treatment of epilepsy, a clinical trial. Epilepsia 14: 329–334, 1973

    Article  PubMed  CAS  Google Scholar 

  • Garrel S, Carraz G, Borselli S. Action anti-épileptique et éléctroencéphalographique du Dépamide. CR. Congress Psychiatry Neurology Langue Française 64: 1030–1033, 1964

    Google Scholar 

  • Gibaldi M, Perrier D. (Eds) Pharmacokinetics, 2nd ed., pp. 319–353, Marcel Dekker, New York, 1982

    Google Scholar 

  • Gugler R, von Unruh E. Clinical pharmacokinetics of valproic acid. Clinical Pharmacokinetics 5: 67–83, 1980

    Article  PubMed  CAS  Google Scholar 

  • Haidukewych D, John G. Chronic valproic acid and coantiepi-leptic drug therapy and incidences of increases in serum liver enzymes. Therapeutic Drug Monitoring 8: 407–410, 1986

    Article  PubMed  CAS  Google Scholar 

  • Haj-Yehia A, Bialer M. Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. Journal of Pharmaceutical Sciences 77: 831–834, 1988

    Article  PubMed  CAS  Google Scholar 

  • Haj-Yehia A, Bialer M. Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity. Pharmaceutical Research 6: 683–689, 1989

    Article  PubMed  CAS  Google Scholar 

  • Kerr BM, Levy RH. Carbamazepine epoxide. In Levy et al. (Eds) Antiepileptic drugs, 3rd ed., pp. 505–520, Raven Press, New York, 1989

    Google Scholar 

  • Kerr BM, Rettie AE, Eddy AC, Loiseau P, Guyot M, et al. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clinical Pharmacology and Therapeutics 46: 82–93, 1989

    Article  PubMed  CAS  Google Scholar 

  • Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clinical Pharmacology and Therapeutics 21: 736–743, 1977

    PubMed  CAS  Google Scholar 

  • Lambert PA. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In Emrich et al. (Eds) Anticonvulsants in affective disorders, pp. 33–44, Experta Medica, Amsterdam. 1984

    Google Scholar 

  • Lambert PA, Carraz G, Borselli S. Action neuropsychotrope d’un novel anti-épileptique: le Dépamide. Annales Médico-Psychologiques 1: 707–710, 1966

    Google Scholar 

  • Lambert PA, Venaud G. Utilisation du valpromide en thérapeutique psychiatrique. L’Encéphale 13: 367–373, 1987

    PubMed  CAS  Google Scholar 

  • Lemperiere T, Feline A, Gutman A. Le Dépamide: problè mes posés par son association à d’autres psychotropes. Annales de Médecine Interne 123: 783–786, 1972

    PubMed  CAS  Google Scholar 

  • Lesur A. Le valpromide, une molécule a redécouvrir. Synapse 36: 81–88, 1987

    Google Scholar 

  • Levy RH. Valproate: modem perspectives. Epilepsia 25 (Suppl. 1): S1–S77. 1984

    Article  Google Scholar 

  • Levy RH, Kerr BM, Loiseau P, Guyst M, Wilensky AJ. Inhibition of carbamazepine epoxide elimination by valpromide and valproic acid. Epilepsia 27: 592. 1986

    Google Scholar 

  • Levy RH, Koch KM. Drug interactions with valproic acid. Drugs 24: 543–546, 1982

    Article  PubMed  CAS  Google Scholar 

  • Levy RH, Shen DD. Valproate: absorption, distribution, and excretion. In Levy et al. (Eds) Antiepileptic drugs, 3rd ed., pp. 583–599. Raven Press, New York, 1989

    Google Scholar 

  • Loscher W, Nau H. Pharmacological evaluation of various metabolites and analogues of valproic acid. Neuropharmacology 24: 427–435, 1985

    Article  PubMed  CAS  Google Scholar 

  • Mairlot F. Analyses de résultats obtenus avec le Dépamide chez des enfants atteints d’instabilité psychomotorice (hyperkiné-sie). Acta Psychiatrica Belgica 79: 201–224, 1979

    Google Scholar 

  • Meijer JWA, Binnie CB, Debets RM, Van Parys JAP, De Beer-Pawlikowski NKB. Possible hazard of valpromide-carbamaz-epine combination therapy in epilepsy. Lancet 1: 802, 1984

    Article  PubMed  CAS  Google Scholar 

  • Musolino R, Gallitto G, Morgante L, Pisani F, Di Perri R. The antiepileptic properties of n-dipropylacetamidc. Acta Neurol-ogica 2: 107–114, 1980

    CAS  Google Scholar 

  • Oreskovic D, Whitlon PS, Pericic D, Markovic Z, Bulal M. Brain gamma-aminobutyric acid and protection from picrotoxininduced convulsions following treatment with di-n-propyla-cetamide and di-n-propylacetic acid. Periodicam Biologorium 89: 17–20, 1987

    CAS  Google Scholar 

  • Oxley J, Hedges A, Makki KA, Monka A, Richens A. Lack of enzyme inducing effect of sodium valproate. British Journal of Clinical Pharmacology 8: 189–190, 1978

    Article  Google Scholar 

  • Pacifici GM, Franchi M, Bencini C, Rane A. Valpromide inhibits human epoxide hydrolase. British Journal of Clinical Pharmacology 22: 269–274, 1986

    Article  PubMed  CAS  Google Scholar 

  • Pacifici GM, Rane A. Valpromide but not sodium hydrogen di-valproate inhibits epoxide hydrolase in human liver. Pharmacology and Toxicology 60: 237–238, 1987

    Article  PubMed  CAS  Google Scholar 

  • Pacifici GM, Tomson T, Bertilsson L, Rane A. Valpromide/carbamazepine and risk of teratogenicity. Lancet 2: 397–398, 1985

    Article  Google Scholar 

  • Pascalis G, Delisle JP, Maes L. Le Dépamide, en dehors des accès maniaques pars. CR. Congress Psychiatry Neurology Langue Française 71: 1026–1034, 1971

    Google Scholar 

  • Pisani F, D’Agastano AA, Fazio A, Oteri G, Pimerano G, et al. Increased dipropylacetic acid bioavailability from dipropyla-cetamide by food. Epilepsia 23: 115–121, 1982a

    Article  PubMed  CAS  Google Scholar 

  • Pisani F, Di Perri R, Nistico G. Rapid quantitation of N-dipro-pyl-acetamide in human plasma by gas-liquid chromatography. Journal of Chromatography 174: 231–233, 1979

    Article  PubMed  CAS  Google Scholar 

  • Pisani F, Di Perri R. Some clinical and pharmacological aspects of n-dipropylacetamide. Italian Journal of Neurological Sciences 4: 245–249, 1980

    Google Scholar 

  • Pisani F, Fazio A, Oteri G, Di Perri R. Dipropylacetic acid plasma levels: diurnal fluctuations during chronic treatment with dipropylacelamide. Therapeutic Drug Monitoring 3: 297–301, 1981

    Article  PubMed  CAS  Google Scholar 

  • Pisani F, Fazio A, Oteri G, Di Perri R. A study on the metabolism of dipropylacetamide to dipropylacetic acid in rats. Journal of Pharmacy and Pharmacology 34: 45–46, 1982b

    Article  PubMed  CAS  Google Scholar 

  • Pisani F, Fazio A, Oteri G, Ruello G, Gitto C, et al. Sodium valproate and valpromide: differential interaction with carb-amazepine in epileptic patients. Epilepsia 27: 548–552, 1986

    Article  PubMed  CAS  Google Scholar 

  • Pisani F, Fazio A, Oteri G, Spira A, Perucca E, et al. Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. British Journal of Clinical Pharmacology 25: 611–613, 1988

    Article  PubMed  CAS  Google Scholar 

  • Porter RJ, Cereghino JJ, Gladding CD, Hessie BJ, Kupferberg HJ, et al. Antiepileptic drug development program. Cleveland Clinical Quarterly 5: 293–305, 1984

    Google Scholar 

  • Puzynski S. Valproic acid amide as a prophylactic agent in schizoaffective disorders. Psychopharmacology Bulletin 20: 151–159, 1984

    PubMed  CAS  Google Scholar 

  • Puzynski S, Klosiewicz L. Valproic acid amide in the treatment of affective and schizoaffective disorders. Journal of Affective Disorders 6: 115–121, 1984

    Article  PubMed  CAS  Google Scholar 

  • Reekers-Ketting JJ, Van der Kleijn E, Leliveld BA, Schobben AFAM, Vree TB. Pharmacokinetics of di-propyl acetate (Depakine) in different dosage forms in man and rhesus monkey. Pharmaceutisch Weekblad 110: 1232–1236, 1975

    CAS  Google Scholar 

  • Richou H, Hug R, Doublet J. Le Dépamide, un psychotrope nor-molhymique (pour de nouveauz schémas thérapeutiques). Annales Médico-Psychologiques 2: 676–684, 1973

    PubMed  CAS  Google Scholar 

  • Riva R, Albani F, Olivi F, Pantaloni M, Baruzzi A. Quantitative determination of n-dipropylacetamide in plasma of epileptic patients by gas-liquid chromatography with nitrogen-selective detection. Journal of Chromatography and Biomedical Applications 233: 371–374, 1982

    Article  CAS  Google Scholar 

  • Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 2nd ed., pp. 17–32, Lea & Febiger, Philadelphia. 1989

    Google Scholar 

  • Rubinstein A, Bialer M, Friedman M, Raz I, Abramsky O. A combined approach to control valproic acid release via novel drug delivery systems of valpromide: a kinetic and a pharmacokinetic study. Journal of Controlled Release 4: 33–38, 1986

    Article  CAS  Google Scholar 

  • Schobben F. Valproic acid: pharmacokinetic aspects. British Journal of Clinical Practice Supplement 27: 48–51, 1983

    Google Scholar 

  • Semadeni GW. Étude clinique de l’effet normothymique du dipropylacetamide. Acta Psychiatrica Belgica 76: 458–466, 1976

    PubMed  CAS  Google Scholar 

  • Stepansky W. A clinical study in the use of valmethamide, an anxiety reducing drug. Current Therapeutic Research 2: 144–149, 1960

    PubMed  CAS  Google Scholar 

  • Vandel S, Bertschy G, Jounet JM, Allers G. Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients. Therapeutic Drug Monitoring 10: 386–389, 1988

    Article  PubMed  CAS  Google Scholar 

  • Vencovsky E. Prophylactic effect of dipropylacetamide by bipolar maniomelancholic psychosis. European Journal of Psychiatry 1: 28–30, 1987

    Google Scholar 

  • Vencovsky E, Soucek K, Kabes J. Prophylactic effect of dipropylacetamide in patients with bipolar affective disorder. In Emrich et al. (Eds) Anticonvulsants in affective disorder, pp. 66–67, Excerpta Medica, Amsterdam, 1984

    Google Scholar 

  • Whitton PS, Oreskovic D, Jernej B, Bulat M. Antiepileptic di-n-propylacetamide and di-n-propylacetic acid increase the noradrenaline turnover in the brain. Periodicum Biologorium 86: 231–234, 1984

    CAS  Google Scholar 

  • Whitton PS, Oreskovic D, Jernej B, Radacic M, Plavsic F, et al. Plasma level of dipropylacetamide and dipropylacetic acid and effect of these drugs on 5-hydroxytryptamine metabolism in mouse brain. Biomedicine and Pharmacotherapy 40: 191–193, 1986

    CAS  Google Scholar 

  • Whitton PS, Oreskovic D, Markovic Z, Skarpa D, Bulta M. Effect of the antiepileptic di-n-propylacetamide on 5-hydroxytryptamine turnover in the brain and 5-hydroxyindolacetic acid level in the cerebrospinal fluid. European Journal of Pharmacology 91: 57–62, 1983

    Article  PubMed  CAS  Google Scholar 

  • Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid- 1988. Clinical Pharmacokinetics 15: 367–389, 1988

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, School of Pharmacy, Hebrew University of Jerusalem, PO Box 12065, Jerusalem, 91120, Israel

    Meir Bialer

Authors
  1. Meir Bialer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bialer, M. Clinical Pharmacology of Valpromide. Clin Pharmacokinet 20, 114–122 (1991). https://doi.org/10.2165/00003088-199120020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199120020-00003

Keywords

Search

Navigation